Table 2 Alemtuzumab patient and RA patient control pooled demographic and serological data. P value: alemtuzumab patients vs established controls. Values in italics are significant (p < 0.05)
Characteristic | Alemtuzumab Treated patients | RA Control patients | P value |
|---|---|---|---|
Age (Years) median, range | 65 [45–81] | 61.5 [52–79] | 0.773 |
Sex male/female, % | 77% F | 87.5% F | 0.600 |
Disease Duration (Years) median, range | 31 [23–40] | 24.5 [20–41] | 0.200 |
Alemtuzumab total dose (mg) median, range | 60 [18–400] | - | - |
DAS-28 median, range | 3.44 [1.38-5.33] | 3.9 [2.03-5.75] | 0.743 |
CRP (mg/L) median, range | 7 [<5-134] | <5 [all <5] | 0.001 |
ESR (mm/hr) median, range | 34 [4–104] | 11.5 [2–38] | 0.03 |
HAQ median, range | 2.25 [2–3] | 1.69 [0.25-2.13] | 0.025 |
VAS median, range | 25 [2–56] | 23 [4–75] | 0.847 |
SJC (n) median, range | 0 [0–2] | 1 [0–7] | 0.414 |
TJC (n) median, range | 1 [0–6] | 3 [0–20] | 0.154 |
IgG (g/L) median, range | 9.5 [6.2 – 16.6] | 9.95 [4.4-16.3] | 0.916 |
IgA (g/L) median, range | 2.6 [1.1 – 4.2] | 1.9 [40.4 -3.9] | 0.431 |
IgM (g/L) median, range | 0.85 [0.006 - 3.2] | 0.85 [0.3 -2.5] | 0.874 |
RF (IU) median, range | 0 [0–67] | 39 [0–275] | 0.060 |
CCP (U/ml) median, range | 0.55 [0–340] | 215 [1.2-340] | 0.039 |